Please assess the completion status of the following clinical trial:

Trial Title: S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed transitional cell carcinoma of the urothelium (bladder, renal pelvis, ureter, or urethra)~  * Metastatic disease~    * Node-positive, non-metastatic disease that is unresectable is allowed~ * Poorly differentiated transitional cell carcinoma OR predominant transitional cell carcinoma with rare foci of squamous differentiation or rare foci of adenocarcinoma allowed~* The following histologic types are not allowed:~  * Adenocarcinoma~ * Small cell carcinoma~ * Sarcoma~ * Squamous cell carcinoma~ * Mixed adeno/squamous/transitional histology~* Measurable disease~  * At least 1 unidimensionally measurable lesion ≥ 2 cm by conventional techniques OR ≥ 1 cm by spiral CT scan~ * Soft tissue disease irradiated within the past 2 months is not considered measurable~* Disease progression or recurrence after 1, and only 1, prior systemic chemotherapy regimen that included cisplatin or carboplatin for metastatic disease~* Not curable by surgery or radiotherapy~* No known brain metastases~PATIENT CHARACTERISTICS:~Age~* Not specified~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* White blood cell (WBC) count ≥ 3,000/mm\^3~Hepatic~* Aspartate aminotransferase (SGOT) / alanine aminotransferase (SGPT) ≤ 2.5 times upper limit of normal (ULN)~* Bilirubin normal~Renal~* Creatinine ≤ 2 times ULN~Cardiovascular~* Corrected QT interval (QTc) \< 500 msec~* Left ventricular ejection fraction (LVEF) \> 40% by Multi Gated Acquisition Scan (MUGA)~* No New York Heart Association class III or IV congestive heart failure~* No myocardial infarction within the past year~* No uncontrolled dysrhythmias~* No poorly controlled angina~* No serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)~* No left ventricular hypertrophy on EKG~* No other significant cardiac disease~Other~* Potassium ≥ 4 mmol/L~* Magnesium ≥ 2 mg/dL~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No prior allergic reaction to compounds of similar chemical or biological composition to FR901228 (depsipeptide)~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunotherapy~Chemotherapy~* See Disease Characteristics~* At least 28 days since prior chemotherapy~* No prior FR901228 (depsipeptide)~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormonal therapy~Radiotherapy~* See Disease Characteristics~* More than 28 days since prior radiotherapy~* No concurrent radiotherapy~Surgery~* More than 28 days since prior surgery~Other~* Recovered from all prior therapy~* More than 28 days since prior intravesical therapy~* No concurrent hydrochlorothiazide~* No concurrent agent that causes QTc prolongation~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent investigational histone deacetylase inhibitor agents or drugs (e.g., sodium valproate)~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Depsipeptide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues